Get the Stockscreener App
1.93
7.82%
0.14
After Hours:
1.88
-0.05
-2.59%
Biora Therapeutics Inc stock is traded at $1.93, with a volume of 139.40K.
It is up +7.82% in the last 24 hours and down -50.51% over the past month.
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.
See More
Previous Close:
$1.79
Open:
$1.81
24h Volume:
139.40K
Relative Volume:
2.02
Market Cap:
$8.10M
Revenue:
$98,000
Net Income/Loss:
$-86.59M
P/E Ratio:
-0.3541
EPS:
-5.45
Net Cash Flow:
$-48.49M
1W Performance:
+19.14%
1M Performance:
-50.51%
6M Performance:
-67.49%
1Y Performance:
-85.91%
1-Day Range:
$1.795
$1.9399
1-Week Range:
$1.55
$1.94
52-Week Range:
$1.43
$19.90
Biora Therapeutics Inc Stock (BIOR) Company Profile
Name
Biora Therapeutics Inc
Sector
Industry
Phone
855-293-2639
Address
4330 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare BIOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOR
Biora Therapeutics Inc
|
1.93 | 8.10M | 98,000 | -86.59M | -48.49M | -5.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Biora Therapeutics Inc Stock (BIOR) Latest News
Biora Therapeutics Reports Q3 2024 Results and Updates - TipRanks
Biora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Highbridge Capital Management's Strategic Acquisition of Biora T - GuruFocus.com
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Biora Therapeutics Advances BioJet Device, Cuts Monthly Expenses 40% Amid Q3 Loss | BIOR Stock News - StockTitan
Biora Therapeutics Inc (BIOR) Q3 2024 Earnings Report Preview: W - GuruFocus.com
Biora Therapeutics Inc (BIOR) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
S&P 500 price target raised at Oppenheimer after 'decisive' election results - Investing.com
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update - GlobeNewswire
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
SEC Form 424B5 filed by Biora Therapeutics Inc. - Quantisnow
SEC Form 424B3 filed by Biora Therapeutics Inc. - Quantisnow
Biora Therapeutics announces $3 million stock and warrant sale - Investing.com India
Biora Therapeutics advances oral drug delivery tech By Investing.com - Investing.com Nigeria
Biora Therapeutics advances oral drug delivery tech - Investing.com India
Biora Therapeutics Shares Progress on Smaller BioJet™ - GlobeNewswire
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting - StockTitan
Progenity Inc stock hits 52-week high of $5.2 amid market fluctuations - Investing.com
Biora Therapeutics Inc’s results are impressive - US Post News
Market Highlights: Biora Therapeutics Inc (BIOR) Ends on a Low Note at 0.55 - The Dwinnex
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting - The Manila Times
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the - GlobeNewswire
Biora Therapeutics enacts reverse stock split, adjusts shares By Investing.com - Investing.com Australia
Biora Therapeutics enacts reverse stock split, adjusts shares - Investing.com India
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium - The Manila Times
Biora Therapeutics Announces Award-Winning Abstract to be - GlobeNewswire
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024 - Yahoo Finance
Biora Therapeutics Inc’s Market Journey: Closing Weak at 0.59, Down -9.63 - The Dwinnex
Biora Therapeutics Inc Inc. (BIOR) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Biora Therapeutics secures additional $4 million financing - Investing.com India
Biora Therapeutics secures additional $4 million financing By Investing.com - Investing.com UK
Biora Therapeutics Achieves ISO 13485 Certification - GlobeNewswire
A History of Outperforming Analyst Forecasts and Beating the Odds: Biora Therapeutics Inc (BIOR) - SETE News
Biora Therapeutics Announces Positive Nasdaq Listing Decision - GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference By Investing.com - Investing.com Canada
Biora Therapeutics secures new financial agreements - Investing.com India
BIOR: Second Quarter Results - Yahoo Finance
Biora Therapeutics, Inc. (NASDAQ:BIOR) Forecasted to Post Q3 2024 Earnings of ($0.42) Per Share - Defense World
BIOR’s Stock Woes: Down -20.37% in 6 Months, Down -20.37% in Just 5 Days - The InvestChronicle
Biora Therapeutics Second Quarter 2024 Earnings: EPS: US$0.18 (vs US$1.47 loss in 2Q 2023) - Yahoo Finance
Biora Therapeutics (NASDAQ:BIOR) Receives “Buy” Rating from HC Wainwright - Defense World
Biora Therapeutics Inc Stock (BIOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):